Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.

Autor:	Rajamaki A; Institute of Clinical Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland., Sorigue M; Medical Department, Trialing Health, Barcelona, Spain. mc.sorigue@zoho.com., Prusila REI; Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland., Kuusisto MEL; Department of Internal Medicine, Länsi-Pohja Central Hospital, Kemi, Finland., Kuitunen H; Department of Internal Medicine, Länsi-Pohja Central Hospital, Kemi, Finland., Jantunen E; Institute of Clinical Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Mercadal S; ICO-Hospital Duran I Reynals, L'Hospitalet, Spain., Turpeenniemi-Hujanen T; Medical Research Center, Oulu University Hospital and Translational Medicine Research Unit, University of Oulu, Oulu, Finland., Sancho JM; Department of Hematology, ICO-Hospital Germans Trias i Pujol, IJC, UAB, Badalona, Barcelona, Spain., Sunela K; Finnish Medicines Agency FIMEA, Barcelona, Spain., Kuittinen O; Institute of Clinical Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Medical Research Center, Oulu University Hospital and Translational Medicine Research Unit, University of Oulu, Oulu, Finland; Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
Jazyk:	angličtina
Zdroj:	Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 06; Vol. 63, pp. 267-272. Date of Electronic Publication: 2024 May 06.
DOI:	10.2340/1651-226X.2024.24377
Abstrakt:	Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and Methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1-2 FL between 1997 and 2016 in nine institutions were included. Results: The median PFS1, PFS2, and PFS3 were 8.1 years (95% confidence interval [CI]: 7-9.3 years), 4.2 years (95% CI: 2.8-5.6 years) and 2.2 years (95% CI 1.7-2.8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset. Interpretation: With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu